Clinical Trial Update: Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a radiolabeled imaging agent for HER2 expression in primary breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• [123I] I-(HE)3-G3 (Iodine-123 labeled HER2-targeted imaging agent)

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Primary Breast Cancer | Phase 1 | Status: COMPLETED